quadrivalent influenza split virion vaccine (Anhui Zhifei Longcom Biopharmaceutical)

Quadrivalent influenza split virion vaccine is an inactivated vaccine developed by Anhui Zhifei Longcom Biopharmaceutical to prevent seasonal influenza. It contains antigens (hemagglutinin) from four different influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The 'split virion' production process involves disrupting the virus particles with detergents, which maintains immunogenicity while potentially reducing reactogenicity compared to whole-virus vaccines. This vaccine is typically administered via intramuscular injection and is intended for use in individuals aged 3 years and older, as investigated in Phase III clinical trials (e.g., CTR20180918) to evaluate its safety and immunogenicity profile.

Other names

quadrivalent inactivated influenza vaccineQIVquadrivalent influenza vaccine (split virion)